Alivus Life Sciences Limited — Board Meeting, 18-08-2026: Outcome of Board Meeting

Alivus Life Sciences' board approved acquiring a 76% stake in IQGEN-X Pharma for ~₹9.12 Cr cash. This expands Alivus's offerings in the API & CDMO space, providing end-to-end solutions. IQGEN-X specializes in pharmaceutical formulation development and reported FY26 turnover of ₹3.48 Cr.